Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.4 USD | +1.41% | -3.04% | +2.64% |
May. 24 | Declaration of Voting Results by DexCom, Inc | CI |
May. 24 | Declaration of Voting Results by DexCom, Inc | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 70.68 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.64% | 50.65B | B- | ||
-5.56% | 181B | C+ | ||
-0.11% | 108B | C | ||
-6.17% | 66.12B | A | ||
+6.58% | 43.11B | B- | ||
+3.40% | 41.3B | B+ | ||
+21.98% | 31.6B | B | ||
+16.81% | 25.03B | A- | ||
-5.81% | 24.16B | A- | ||
-4.35% | 23.95B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCM Stock
- Ratings DexCom, Inc.